| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ocular Therapeutix, Inc. (OCUL) has 9 insiders with recent SEC Form 4 filings, including 11 buys and 0 sells. OCUL is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 394.7K | $3.94M | - | |
| Other | 389.3K | $3.88M | - | |
| Other | 330.7K | $3.30M | - | |
| Other | 326.3K | $3.25M | - | |
| Other | 323.4K | $3.22M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 5, 2019 | Sawhney Amarpreet | Chairman Of The Board | Buy | 45,780 | $2.91 | $133,349.08 | +2.6% | |
| May 28, 2019 | Goldstein Michael H. | Chief Medical Officer | Buy | 12,000 | $2.51 | $30,120.00 | +87.7% | |
| Mar 15, 2019 | Heier Jeffrey S.61 | Director | Buy | 24,000 | $4.15 | $99,600.00 | New | |
| Mar 15, 2019 | Goldstein Michael H. | Chief Medical Officer | Buy | 10,000 | $4.15 | $41,500.00 | +271.3% | |
| Mar 13, 2019 | Lindstrom Richard L Md65 | Director | Buy | 56,441 | $4.33 | $244,389.53 | +129.6% | |
| Dec 14, 2018 | Hanley Kevin F. | See Remarks | Buy | 10,000 | $5.50 | $55,000.00 | +100.0% | |
| Dec 10, 2018 | Hanley Kevin F. | See Remarks | Buy | 10,000 | $5.60 | $56,000.00 | New | |
| Dec 6, 2018 | Bollag Daniel M | See Remarks | Buy | 17,400 | $5.76 | $100,224.00 | +70.4% | |
| Aug 20, 2018 | Mattessich Antony C.47 | President &CEO | Buy | 20,000 | $5.95 | $119,000.00 | +52.8% | |
| Aug 14, 2018 | Notman Donald | Chief Financial Officer | Buy | 12,500 | $6.29 | $78,625.00 | +260.4% |